AstraZeneca Plc $AZN Shares Sold by Bessemer Group Inc.

Bessemer Group Inc. reduced its holdings in AstraZeneca Plc (NYSE:AZN – Free Report) by 61.5% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 14,693 shares of the company’s stock after selling 23,440 shares during the quarter. Bessemer Group Inc.’s holdings in AstraZeneca were worth $2,373,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Aries Wealth Management increased its position in shares of AstraZeneca by 1.3% during the third quarter. Aries Wealth Management now owns 4,546 shares of the company’s stock worth $741,000 after acquiring an additional 60 shares in the last quarter. Triumph Capital Management lifted its position in AstraZeneca by 32.6% in the 3rd quarter. Triumph Capital Management now owns 252 shares of the company’s stock valued at $41,000 after acquiring an additional 62 shares in the last quarter. Claro Advisors Inc. boosted its stake in AstraZeneca by 5.2% in the 3rd quarter. Claro Advisors Inc. now owns 1,247 shares of the company’s stock worth $201,000 after purchasing an additional 62 shares during the period. Davis Investment Partners LLC boosted its stake in AstraZeneca by 3.4% in the 3rd quarter. Davis Investment Partners LLC now owns 1,868 shares of the company’s stock worth $302,000 after purchasing an additional 62 shares during the period. Finally, Riversedge Advisors LLC increased its holdings in AstraZeneca by 2.9% during the 3rd quarter. Riversedge Advisors LLC now owns 2,347 shares of the company’s stock worth $379,000 after purchasing an additional 67 shares in the last quarter. Institutional investors own 20.35% of the company’s stock.

AstraZeneca Stock Performance

Shares of NYSE AZN opened at $174.20 on Friday. The company has a debt-to-equity ratio of 0.51, a current ratio of 1.01 and a quick ratio of 0.79. The firm has a market cap of $270.17 billion, a price-to-earnings ratio of 24.64, a P/E/G ratio of 1.35 and a beta of 0.24. AstraZeneca Plc has a one year low of $153.41 and a one year high of $212.71. The stock’s fifty day moving average price is $170.72 and its two-hundred day moving average price is $180.02.

AstraZeneca (NYSE:AZN – Get Free Report) last released its quarterly earnings results on Saturday, October 31st. The company reported $2.79 earnings per share for the quarter, beating analysts’ consensus estimates of $2.60 by $0.19. AstraZeneca had a net margin of 17.68% and a return on equity of 31.85%. The company had revenue of $16.21 billion during the quarter, compared to the consensus estimate of $16 billion. During the same period in the previous year, the business earned $2.38 earnings per share. The firm’s quarterly revenue was up 6.5% on a year-over-year basis. On average, equities analysts forecast that AstraZeneca Plc will post 10.22 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the company. Deutsche Bank upgraded AstraZeneca from a “sell” rating to a “hold” rating in a report on Tuesday, September 15th. Zacks Research raised AstraZeneca from a “strong sell” rating to a “hold” rating in a research report on Tuesday, October 13th. Royal Bank Of Canada assumed coverage on shares of AstraZeneca in a research note on Tuesday, September 8th. They set an “outperform” rating for the company. Nordea Equity Research upgraded shares of AstraZeneca from a “sell” rating to a “buy” rating in a report on Tuesday, October 13th. Finally, Wall Street Zen upgraded shares of AstraZeneca from a “hold” rating to a “buy” rating in a report on Saturday, October 31st. Sixteen investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $206.67.

Get Our Latest Report on AstraZeneca

AstraZeneca Company Profile

(Free Report)

AstraZeneca plc is a global, science-led biopharmaceutical company headquartered in Cambridge, United Kingdom. The company discovers, develops and commercializes prescription medicines, with a focus on oncology, biopharmaceuticals and rare diseases. Its research and commercial operations serve patients and healthcare systems across more than 100 countries. AstraZeneca’s portfolio includes medicines for cancer, respiratory and immune-mediated conditions, cardiovascular, renal and metabolic diseases, and rare disorders.

Featured Stories

Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca Plc (NYSE:AZN – Free Report).

Institutional Ownership by Quarter for AstraZeneca (NYSE:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.